Empowered Funds’s Sage Therapeutics SAGE Stock Holding History

Empowered Funds’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,840	Closed	-$150K	–	1834
2025 Q1	$150K	Buy	18,840 +2,160	+13%	+$15.8K	﹤0.01%	1536
2024 Q4	$90.6K	Buy	+16,680	New	+$102K	﹤0.01%	1589
2023 Q3	–	Sell	-57,153	Closed	-$2.69M	–	1261
2023 Q2	$2.69M	Buy	+57,153	New	+$2.84M	0.09%	309

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Empowered Funds's SAGE Position: Q2 2025 in Review

Empowered Funds sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 18,840 shares — an estimated $150K sold.

Empowered Funds first reported a position in SAGE in Q2 2023 and held it in 3 quarters. The position peaked at $2.69M in Q2 2023. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

Empowered Funds reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
Empowered Funds sold 18,840 Sage Therapeutics shares in Q2 2025, an estimated $150K.
Empowered Funds first reported a position in Sage Therapeutics in Q2 2023 and held it in 3 quarters.
Empowered Funds's Sage Therapeutics position peaked at $2.69M in Q2 2023.
192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Empowered Funds's 13F filing for Q2 2025, filed 11 Aug 2025.